➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Express Scripts
Boehringer Ingelheim
McKesson
Merck

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Litigation Details for GILEAD SCIENCES, INC. v. Mylan Inc. (N.D.W. Va. 2014)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in GILEAD SCIENCES, INC. v. Mylan Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in GILEAD SCIENCES, INC. v. Mylan Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for GILEAD SCIENCES, INC. v. Mylan Inc. (N.D.W. Va. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-06-09 1 31. United States Patent No. 6,703,396 (“the ’396 Patent,” copy attached as Exhibit B),… Infringement of U.S. Patent No. 6,703,396 54. Plaintiffs repeat…Exhibit A - Patent Information, # 2 Exhibit A/Pt. 2 - Patent Information, # 3 Exhibit B - Patent Information…Information, # 4 Exhibit C - Patent Information, # 5 Exhibit C/Pt. 2 - Patent Information, # 6 Civil Cover Sheet… 1. This is an action for patent infringement under the patent laws of the United States, Title External link to document
2015-03-02 105 infringement of U.S. Patent Nos. 6,642,245 (the “’245 patent”), 6,703,396 (the “’396 patent”), and 8,592,397…infringement of a fourth patent, U.S. Patent No. 8,716,264 (the “’264 patent”). (D.I. 94.) (The ‘245… ‘396 patents are referred to herein as the “FTC Patents,” and the ‘397 and ‘264 patents are referred…before the United States Patent and Trademark Office of the patent applications leading to…before the United States Patent and Trademark Office of the patent applications leading to External link to document
2015-03-02 106 United States Patent and Trademark Office (“USPTO”) issued United States Patent No. 6,642,245 (the “’245… ’245 patent, including but not limited to the right to sue for infringement of the ’245 patent. …the USPTO issued United States Patent No. 6,703,396 (the “’396 patent”), entitled “Method of Resolution… ’396 patent, including but not limited to the right to sue for infringement of the ’396 patent. …the USPTO issued United States Patent No. 8,592,397 (the “’397 patent”), entitled “Compositions and Methods External link to document
2015-03-26 125 Exhibit Decl of Wm Adams and Exh. 1-3 terms of U.S. Patent Nos. 6,642,245 (“the ’245 Patent”), 6,703,396 (“the ’396 Patent”), 8,592,397 (… (“the ’397 Patent”), and 8,716,264 (“the ’264 Patent”) that are in dispute and proposed constructions…asserting Claim 6 of the ‘245 Patent; Claims 1, 3-5, 13, 15, and 16 of the ‘396 Patent; Claims 1-6, 14-16, 19…24-26 of the ‘397 Patent; and Claims 1-3, 9-17, 25, 33, and 34 of the ‘264 Patent (collectively, “the…the currently Asserted Claims. I. ‘245 Patent External link to document
2015-03-30 127 Its Proposed Claim Constructions for U.S. Patent Nos. 8,592,397 and 8,716,264, that this term is a limitation…;s performance of its duty as the construer of patent claims.” Indeed, the Federal Circuit has never …claim language when it decided to challenge the patents-in-suit— it alleged neither indefiniteness nor…2014 2 November 2015 1:14-cv-00099 830 Patent None District Court, N.D. West External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Boehringer Ingelheim
Baxter
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.